QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touchService navigator

QPS Neuropharmacology is the division of QPS that focuses on preclinical studies in CNS diseases, Orphan Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS Neuropharmacology the first choice for most CNS drug development needs.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader in the CRO industry, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

Why choose us?

Customer satisfaction is our absolute priority

Your timeline is our timeline

f

Every study is custom-built

p

Scientific input to study design and data interpretation

Extensive experience with virtually all drug targets and treatment types

0

Wide range of validated models and techniques for comprehensive compound tests from a single source

AAALAC certification ensures highest quality standards

QPS Austria AAALAC accrediation Logo

QPS NEURO NEWS

Neurofilament light chain – biomarker of high translational value!

 Neurofilament light chain – biomarker of high translational value!

Biomarkers and their use in neurodegenerative disease research delineates a rising area of research and may provide an important link between preclinical disease models and evaluation of disease progression in patients. Neurofilament light chain (NF-L), a neuronal cytoplasmic protein, is increased in a variety of neuronal diseases due to axonal damage. A strong increase of NF-L levels was found in ALS (Amyotrophic Lateral Sclerosis) patients (Gaetani et. al, 2018). Therefore, NF-L levels were investigated in the low copy transgenic mouse model SOD1-G93A. Increased plasma NF-L levels were observed already at an age of 24 weeks, reaching significance with 27 weeks (Fig. 1). In the familial Alzheimer’s disease mouse model 5xFAD an increase in plasma NF-L levels can be observed already at an age of 6 months (Fig. 2A). Additionally, strongly elevated CSF NF-L levels can be detected in 9 month old 5xFAD mice (Fig. 2B).



Figure 1: Quantification of neurofilament light chain in plasma of low copy SOD1-G93A mice.
NF-L levels in pg/mL in the plasma of 24, 27 and 30 week old SOD1-G93A mice compared to non-transgenic littermates (ntg). Two-way ANOVA with Tukey’s post hoc test. Mean + SEM. *p<0.05; ***p<0.001. *compared to ntg; # differences between age groups.

Figure 2: Quantification of neurofilament light chain in plasma and CSF of 5xFAD mice. A: NF-L levels in pg/mL in the plasma of 3, 6, 9 and 12 month old 5xFAD mice compared to non-transgenic littermates (ntg). Two-way ANOVA with Bonferroni‘s post hoc test. B: NF-L levels in pg/mL in the CSF of 9 months old 5xFAD mice compared to ntg. Unpaired t-test. A and B: Mean + SEM. *p<0.05; **p<0.01; ***p<0.001.

Meet us at the Neuroscience 2019 conference of the SfN in Chicago, IL, USA

Meet us at the Neuroscience 2019 conference of the SfN in

Chicago, IL, USA


The QPS Neuropharmacology team will attend the Neuroscience 2019 conference and is pleased to meet you at our booth # 1464.

Additionally, our scientists are presenting our newest research results in four posters:

21st of october


I41: „Characterization of relevant mouse models for new biomarker” Vera Niederkofler, Tina Loeffler, Stefanie Flunkert, Agnes Kasza, Ewald Auer, Birgit Hutter-Paier

H30: “Behavioral characterization of low copy SOD1 G93A transgenic mice” Stefanie Flunkert, Roland Rabl, Agnes Kasza, Vera Niederkofler, Ewald Auer, Birgit Hutter-Paier

23rd of october


E11: “Relevance of choice of brain region and time point of analysis after MPTP lesioning in wild type mice” Jan Kehr, Victoria Schiffer, Shimako Yoshitake, Tina Loeffler, Vera Niederkofler, Stefanie Flunkert, Ewald Auer, Takashi Yoshitake, Birgit Hutter-Paier

D5: “Characterization of 4L/PS-NA mice for different biomarkers to model Gaucher disease” Stefanie Flunkert, Staffan Schmidt, Tina Loeffler, Vera Niederkofler, Joerg Neddens, Maria Posch, Ewald Auer, Jan Kehr, Birgit Hutter-Paier

Join us from October 19-23 at McCormick Place in Chicago, IL, USA

Scientific Posters

Webinar “Predictive Disease Models for CNS Drug Development“

In November 2018, Birgit Hutter-Paier, PhD, the Director of Neuropharmacology at QPS Austria presented this webinar about validated transgenic and non-transgenic in vitro and in vivo models covering most targets of AD, PD, HD and other neurodegenerative diseases.

Birgit Hutter-Paier

  You will learn:

  • When to use animal models in your drug discovery program
  • How to choose the most appropriate animal model for your therapeutic or mechanism of action
  • How to design the most efficient “first-pass” proof-of-concept study
  • Best practices for submitting compounds and sample requirements for a successful study

Brought to you by ADDF ACCESS, a program of the ADDF and Science Exchange, as part of their commitment to connect researchers developing CNS drugs with technologies that can help accelerate breakthrough discoveries.

Format: 30 minutes with 10 minutes Q&A

Watch recording!

In Vitro Services

QPS Austria’s Neuropharmacology Department provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.

In Vivo Services

We have more than 15 years experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects. Several customized behavioral tests, including motor, cognitive, and emotional assays, are offered to phenotype mouse and rat models and to evaluate effects of compounds in different in vivo models.

Ex Vivo Services

Our ex vivo services cover a full range of histological services, a biobank composed of various specimen derived from our in-house in vivo and in vitro models, and numerous well established tests for biomarkers. We are happy to test new protocols and establish new markers to meet your specific needs.

Facebook
Twitter
LinkedIn